Table 3.
Phase 3 trials of thalidomide maintenance therapy after autologous SCT for myeloma
T indicates thalidomide; Pam, pamidronate; Pred, prednisone; and NS, not significant.
Phase 3 trials of thalidomide maintenance therapy after autologous SCT for myeloma
T indicates thalidomide; Pam, pamidronate; Pred, prednisone; and NS, not significant.
